Dr. Castro is the Founder and CEO of Bio-Synthesis Inc., where he established scientific collaborations for nucleic acid based diagnostics and therapeutics, using a new generation of nucleic acids analogs. Dr. Castro is an expert in synthetic DNA/RNA chemistry. Under his leadership, Bio-Synthesis developed diagnostic, clinical, and therapeutic applications of Bridged Nucleic Acids (NC-BNAs), modified nucleic acids with stronger selectivity, binding and stability for RNA blockade, antisense, clamping, and many other life sciences applications. Dr. Castro’s many contributions also include applications of peptide chemistry in immunology proteomics, epigenomics, DNA identification, DNA diagnostics, and efficient and accurate diagnostic testing, which is based on both DNA and peptides methodologies. Dr. Castro is responsible for the chemical synthesis of our lead compound for triple negative breast cancer.
Dr. Siciliano co-founded Invisible Sentinel in 2006 and was the lead inventor of the Company’s Veriflow technology. In his role as CEO, he sets corporate strategy, including sales & marketing initiatives and the identification of strategic partnerships. He also continues to lead the R&D team, drawing on his more than 15 years of experience in microbiology, immunology, and assay development. He is the honoree on the annual "40 under 40" list compiled by the Philadelphia Business Journal to recognize outstanding entrepreneurs and business leaders. He’s also the awardee of the 2015 Marcum/Smart CEO Innovator of the Year.
Dr. Francher is an independent pharmaceutical consultant with over 30 years of experience in business development and leadership of cross-functional development teams and strategic planning. As a Global Product Vice President in Oncology at AstraZeneca, Donna led the development teams for Caprelsa® and Faslodex® through late stage development that culminated in NDA, EMA and rest-of-world approvals for medullary thyroid cancer and advanced breast cancer, respectively. She also led the Iressa product team through life cycle management indications, as well as leading other development projects such as selumetinib, tremilimumab and cediranib. As a consultant, she has worked with Array Biopharma, Sanofigenzyme, Syndax and Radius Pharmaceuticals on a variety of strategic development opportunities. Donna is a business advisor for the Philadelphia Science Center’s QED program and an IRB member of the Crozer Keystone Health System.
Dr. Rigaut is a partner at Howson & Howson LLP. She has extensive experience in patent prosecution, including preparation and filing of patent applications, amendments and responses to PTO Official Actions on a variety of subjects including cancer genes, transgenic plants, RNA viruses, monoclonal antibodies, antisense technologies, and compositions involved in anti-inflammatory responses. She also prepared patentability and freedom to operate opinions.
Mr. Toner is a partner in the Corporate Practice Group at Duane Morris LLP. His practice focuses primarily on advising companies in connection with mergers, acquisitions and divestitures, private equity investments, joint ventures, and strategic alliances. Mr. toner has significant experience with complex commercial transactions in various industries including biotechnology, pharmaceuticals, and medical devices. He is listed in Chambers USA: American’s leading Lawyers for Business for Corporate/M&A.